The last few years have been quiet for biopharma M&A, and an increasingly muscular US Federal Trade Commission is regularly cited as a reason. The agency’s scrutiny of proposed deals has certainly stepped up, but to what extent can the antitrust regulator be blamed for this apparent dip in activity?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,